Aligos Therapeutics Inc — Balance Sheet (NASDAQ:ALGS) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 265.3 M235.37 M146.69 M151.53 M70.09 M Total liabilities 45.26 M50.64 M42.79 M59.45 M99.07 M Total equity 220.04 M184.73 M103.9 M92.08 M28.97 M Total liabilities & shareholders' equities 265.3 M235.37 M146.69 M151.53 M70.09 M Total debt ————— Net debt —————

뉴스

H.C. Wainwright bestätigt Kaufempfehlung für Aligos Therapeutics nach Fortschritten bei Pevifoscorvir

Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress

Aligos Therapeutics: Fortschritte bei Phase-2-Studie zu Hepatitis B treiben Aktie an

Aligos Therapeutics stock rises on Phase 2 HBV study progress

Aligos meldet Fortschritte bei Phase-2-Studie zu Hepatitis-B-Medikament

Aligos reports progress on Phase 2 hepatitis B drug study

Aligos Therapeutics ernennt James Hassard zum Chief Commercial Officer

Aligos therapeutics appoints James Hassard as chief commercial officer

UBS startet Aligos Therapeutics mit Kaufempfehlung – Pipeline für Lebererkrankungen im Fokus

Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline

Aligos: THR-β-Agonist verstärkt Gewichtsverlust in Kombinationstherapie

Aligos reports synergistic weight loss effect with THR-β agonist